Rosetta Genomics Appoints Ana C. Ward as Executive Vice President, Legal and Corporate Development
February 29 2016 - 9:00AM
Business Wire
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics,
announces the appointment of Ana C. Ward, Esq. as Executive Vice
President, Legal and Corporate Development. Ms. Ward will join
Rosetta Genomics as of March 1, 2016 and will work primarily from
the Company’s Lake Forest, California facility.
Ms. Ward brings to Rosetta Genomics nearly 20 years of legal and
business experience in biotechnology and healthcare, with a
particular emphasis on intellectual property, corporate development
transactions, and employment law. Most recently she was Chief
Operating Officer of Aptamir Therapeutics, a biotechnology
start-up focused on the development of microRNA-based therapeutics
for the treatment of obesity and other metabolic diseases.
Previously she was General Counsel and Senior Vice President for
Asuragen, Inc. and its spin-off, Mirna Therapeutics, where she
managed a diverse portfolio of legal matters, including FDA, GMP,
GLP, and CLIA compliance and regulations, intellectual property and
litigation. Prior to that, Ms. Ward was general counsel of Ambion,
where she oversaw the sale of Ambion to Applied Biosystems (now
ThermoFisher Scientific) and spin-off of Asuragen. Prior to Ambion,
Ms. Ward was Senior Intellectual Property Counsel with Yum! Brands
and an Intellectual Property Associate in the Dallas office of
Sidley Austin. Ms. Ward began her career as Intellectual Property
Counsel for Applied Science Fiction in Austin, Texas.
“We are delighted to welcome Ana to the Rosetta Genomics team.
Her legal and business experience are tailor-made for Rosetta,
while her experience with microRNA diagnostics and therapeutics
will be of great value as we continue to build Rosetta into a
leading molecular diagnostics company focused on enabling truly
personalized medicine,” said Kenneth A. Berlin, President and Chief
Executive Officer of Rosetta Genomics.
“I look forward to leveraging my business experience and legal
expertise to benefit Rosetta Genomics as we continue to build and
expand our high-value molecular testing services across a number of
important medical specialties,” said Ms. Ward. “Rosetta’s broad and
deep intellectual property portfolio offers multiple opportunities
for monetization and partnership. I look forward to working with
the Rosetta Genomics team to realize that potential.”
Ms. Ward holds a BA in French and a MS in Molecular Biology and
an MBA, all from the University of Texas, Austin, and a J.D. from
the University of Texas Law School. Ms. Ward also holds an MS in
Bioscience Regulatory Affairs from Johns Hopkins University. She is
admitted to practice law in the State of Texas and is registered to
practice before the U.S. Patent & Trademark Office.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based and other molecular diagnostics. Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company now offers core FISH, IHC and
PCR-based testing capabilities and partnerships in Pathology,
Oncology and Urology that provide additional content and platforms
that complement Rosetta’s microRNA and Next-Gen Sequencing
offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the
diagnosis of indeterminate thyroid FNA smears, as well as the full
RosettaGX™ portfolio of cancer testing services are commercially
available through the Company’s Philadelphia, PA- and Lake Forest,
CA-based CAP-accredited, CLIA-certified labs, respectively. For
more information visit www.rosettagx.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects including, but not limited
to statements relating to Rosetta Genomics expanding its
testing menu, enabling personalized medicine, monetizing its
intellectual property portfolio, entering into partnerships and
having a leadership position in the diagnostics market constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including those risks more fully discussed in the "Risk
Factors" section of Rosetta’s Annual Report on Form 20-F for the
year ended December 31, 2014 as filed with the SEC. In
addition, any forward-looking statements represent Rosetta’s views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Rosetta does
not assume any obligation to update any forward-looking statements
unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160229005649/en/
Rosetta Genomics Contact:Ken Berlin,
267-298-1159President &
CEOinvestors@rosettagenomics.comRosetta Genomics Investor
Contact:LHAAnne Marie Fields, 212-838-3777afields@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Sep 2023 to Sep 2024